AuriGen Medical has recently won the Global Innovation Award at the ICI conference in Isreal. This award attracts medical device and pharmaceutical start-ups from all around the world.
AuriGen Medical specializes in the treatment of an irregular heartbeat known as atrial fibrillation, and is currently developing an implant that treats stroke and heart failure risk associated with atrial fibrillation.
“This validation will help to increase our visibility and accelerate the development of AuriGen’s technology, which will deliver hope to the countless patients with this condition,” says Dr. John Thompson, CEO of AuriGen Medical.
Over 30 million patients suffer with atrial fibrillation, a condition that can lead to stroke, dementia, heart failure, and death. Currently, the treatment options are customary and often ineffective, which can result in expensive healthcare costs.
The AuriGen Device uses a patented sensor and implant technology that safely isolates the source of atrial fibrillation and filters blood clots. This prevents the blood clots from going to the brain and reduces the risk of stroke.